Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05204407 · ClinicalTrials.gov registry record · NA
Luteolin for the Treatment of People With Schizophrenia
A NA study of Schizophrenia and Schizoaffective Disorder, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 85
- Enrollment target
- 2
- Study locations
NCT05204407 is a NA study of Schizophrenia and Schizoaffective Disorder that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 85 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05204407, a NA study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
- 2
- Study locations
Study Summary
Luteolin is a natural product found in foods such as celery, green pepper, parsley, and chamomile tea. It has been found to have anti-cancer, anti-oxidant, and anti-inflammatory properties. The purpose of this study is to determine if luteolin helps improve symptoms of schizophrenia.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Luteolin
Study Locations (2)
California
- University of California, Los Angeles - Los Angeles
Maryland
- Maryland Psychiatric Research Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2026-01-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05204407
The ClinicalTrials.gov registry entry for NCT05204407 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (61% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05204407 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.
Frequently Asked Questions
What is clinical trial NCT05204407 about?
NCT05204407 is a clinical study titled "Luteolin for the Treatment of People With Schizophrenia". Luteolin is a natural product found in foods such as celery, green pepper, parsley, and chamomile tea. It has been found to have anti-cancer, anti-oxidant, and anti-inflammatory properties. The purpose of this study is to determine if luteolin helps improve symptoms of schizophrenia.
What is the current status of trial NCT05204407?
This trial is currently completed. It is a NA study. The enrollment target is 85 participants. The study started on 2022-06-13. Estimated completion is 2026-01-14.
What conditions does trial NCT05204407 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT05204407?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Luteolin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05204407?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05204407 being conducted?
This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.